Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Bertoni

Showing results (181-190 of 325) with videos related to

Pageof 33
Sort By:
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2004
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio Cogliatti, et al.
Human Pathology|February 3, 2007
Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 casesCristina Campidelli, Elena Sabattini, Milena Piccioli, et al.
Cancers|January 19, 2018
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell LymphomasCecilia Bandini, Aldi Pupuleku, Elisa Spaccarotella, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
British Journal of Haematology|April 15, 2011
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOPMonica Testoni, Ivo Kwee, Timothy C Greiner, et al.
Nature|May 5, 2009
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphomaMara Compagno, Wei Keat Lim, Adina Grunn, et al.
Life Science Alliance|April 27, 2023
Myc controls NK cell development, IL-15-driven expansion, and translational machineryHanif J Khameneh, Nicolas Fonta, Alessandro Zenobi, et al.
Journal of Translational Medicine|February 1, 2012
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemiaPietro Bulian, Davide Rossi, Francesco Forconi, et al.
Pageof 33

Showing results (181-190 of 325) with videos related to

Sort By:
Pageof 33
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2004
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio Cogliatti, et al.
Human Pathology|February 3, 2007
Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 casesCristina Campidelli, Elena Sabattini, Milena Piccioli, et al.
Cancers|January 19, 2018
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell LymphomasCecilia Bandini, Aldi Pupuleku, Elisa Spaccarotella, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
British Journal of Haematology|April 15, 2011
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOPMonica Testoni, Ivo Kwee, Timothy C Greiner, et al.
Nature|May 5, 2009
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphomaMara Compagno, Wei Keat Lim, Adina Grunn, et al.
Life Science Alliance|April 27, 2023
Myc controls NK cell development, IL-15-driven expansion, and translational machineryHanif J Khameneh, Nicolas Fonta, Alessandro Zenobi, et al.
Journal of Translational Medicine|February 1, 2012
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemiaPietro Bulian, Davide Rossi, Francesco Forconi, et al.
Pageof 33